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ABSTRACT
Background: The comprehensive International
Classification of Functioning, Disability and Health (ICF)
Core Set for rheumatoid arthritis (RA) is a selection of 96
categories from the ICF, representing relevant aspects in
the functioning of patients with RA.
Objectives: To study the responsiveness of the ICF Core
Set for RA in rheumatological practice.
Methods: A total of 46 patients with RA (72% women,
mean (SD) age 53.6 (12.6) years, disease duration 6.3
(8.0) years) were interviewed at baseline and again after
6 months treatment with a disease-modifying antirheu-
matic drug (DMARD), applying the ICF Core Set for RA
with qualifiers for problems on a modified three-point
scale (no problem, mild/moderate, severe/complete).
Patient-reported outcomes included Modified Health
Assessment Questionnaire (MHAQ) and Short-Form 36
(SF-36) health survey, and disease activity was calcu-
lated. Responsiveness was measured as change in
qualifiers in ICF categories, and was also compared with
change in patient-reported outcomes.
Results: After 6 months of DMARD treatment,
improvement by at least one qualifier was seen in 20% of
patients (averaged across all ICF categories), 71%
experienced no change and 9% experienced worsening
symptoms. Findings were similar across the different
aspects of functioning. Mainly moderate effect sizes were
seen for 6-month changes in the ICF Core Set for RA,
especially in patients with improved health status, with
similar effect size for disease activity. The components in
the ICF Core Set for RA were only weakly associated with
patient-reported outcomes and disease activity.
Conclusions: The ICF Core Set for RA demonstrated
moderate responsiveness in this real-life setting of
patients where minor changes occurred during treatment
with DMARDs.
Rheumatoid arthritis (RA) is a chronic disabling
disease which is often associated with limitations
in physical, mental and social function,1 2 and with
work disability.3 4 The framework of the World
Health Organization (WHO) International
Classification of Functioning, Disability and
Health (ICF) can be used to describe and assess
daily functioning and disability from a biopsycho-
social perspective in all aspects of health. This
framework for the description of health and
health-related conditions5 includes the components
Body Functions and Structures, Activities and
Participation, Environmental Factors and Personal
Factors. Components are further defined by the so-
called ICF categories. To rate the magnitude or the
severity of the problem in each of the ICF
categories, the WHO has proposed a so-called
qualifiers’ scale, which is scored by a health
professional during a patient interview.
In order to facilitate the application of the ICF in
clinical practice, specific Core Sets were developed
for specific diseases as shortlists of ICF categories,
which are important for patients. The comprehen-
sive ICF Core Set for RA represents the typical
spectrum in functioning of patients with RA with
a selection of 96 categories6 in the 4 components of
Body Functions (b), Body Structures (s), Activities
and Participation (d) and Environmental Factors
(e),6 and this core set was developed by experts in a
formal decision-making and consensus process
based on evidence of preliminary studies.
The introduction of the ICF had a positive effect
on staff satisfaction with multidisciplinary team care
in a day patient setting7 and on satisfaction among
patients with RA.8 The ICF has recently shown
validity against therapist formulated goals in patients
with RA.9 The present ICF Core Set for RA has also
been validated from the patient perspective.10 11
The development of ICF Core Sets with quali-
fiers raises the questions of reliability, validity and
also responsiveness when applied in clinical prac-
tice, since the use of qualifiers opens the possibility
of registering change over time. Thus, in spite of
the ambiguity of how to use the ICF, the
exploration of responsiveness is necessary to draw
conclusions on psychometric properties, longitudi-
nal validity and future development of the
qualifiers in patient populations.12
The ICF Core Set for RA has recently demon-
strated low to moderate reliability,13 but exploratory
examination of the qualifiers’ scale of the ICF Core
Set for RA also suggested better feasibility and
higher reliability when the number of qualifiers was
reduced to three for all ICF categories.13 Validation
has not yet been performed in a longitudinal setting
and especially not in a real-life setting where less
changes are expected during treatment of RA
opposed to randomised clinical trials.
This study had the objective of examining the
responsiveness of the ICF Core Set for RA in patients
who were given disease-modifying antirheumatic
drugs (DMARDs) in a real-life setting. Changes in
ICF were also related to changes in established
patient-reported outcomes and disease activity.
PATIENTS AND METHODS
Study design
We conducted a responsiveness study with assess-
ments at two time points 6 months apart in patients
with RA starting with DMARD treatment.
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Patients
A sample of 61 home-dwelling patients diagnosed with RA14 by
their treating rheumatologist were included in the study after
written informed consent was obtained. Patients were recruited
consecutively from the rheumatology outpatient department at
the Diakonhjemmet Hospital in Oslo, Norway where they, as a
routine part of a DMARD prescription, are included into the
NOR-DMARD project which is a follow-up study after
DMARD prescription.15 After 6 months, 46 patients had
completed the study with all assessments and were eligible for
the present analyses.
Data collection
Patients were interviewed twice, at the first time point (T1) and
again after 6 months (mean 191 days) (second time point (T2)).
Interviews at T1 and T2 were performed by the same examiner,
either by an occupational therapist (SR, n = 29) or a phy-
siotherapist (RHM, n = 17) not involved in the clinical
treatment of the patients. The interviews were scheduled
separately from the appointments for clinical treatment at the
outpatient department. Both interviewers had reviewed ICF
Core Set instruction and were trained according to a video
issued by the ICF branch of the WHO.
The assessors rated during the interview the magnitude or the
severity of the problem in each of the ICF categories, going one
by one through all ICF categories and using all obtained
information.
Measures
Demographics and medical treatment
At baseline, age, gender, disease duration in years, level of
education ((12 years/.12 years), presence of erosions and
rheumatoid factor (RF) were recorded. Use of the following
drugs at baseline was recorded (yes/no): non-steroidal antirheu-
matic drugs, cyclo-oxygenase 2 inhibitors and glucocorticoids.
The DMARD that was initiated at baseline was recorded as
monotherapy (predominantly methotrexate), combination of
conventional DMARDs, or biological drug.
ICF Core Set for RA
The ICF Core Set for RA includes 25 categories from the
component body functions, 18 from the component Body
Structures, 32 from the component Activities and Participation
and 21 from the component Environmental Factors.6 The
severity of a patient’s problem in each of the ICF categories is
quantified with the qualifier scale, which for the components
Body Functions and Structures, and Activities and Participation
originally had five response levels, each ranging from 0 to 4,
corresponding to no/mild/moderate/severe/complete impair-
ment. For example, a moderate problem with walking would
give a score of 2. The qualifier scale of the component
Environmental Factors originally had nine response levels
indicating four degrees of a possible barrier, one level represent-
ing no influence and four degrees of a possible facilitator.
Based on previous findings of improved reliability and
feasibility with fewer response levels,13 we applied three
response levels for the qualifier: no impairment (0), mild or
moderate impairment (1) and severe or complete impairment
(2). Environmental factors were also graded with three response
levels: being a barrier (21), having no influence (0) or being a
facilitator (+1). Additional response options for ICF categories
were ‘‘not specified’’8 and ‘‘not applicable’’9 for each ICF
category.
Patient-reported outcomes
Patients filled in self-administered questionnaires at baseline
and after 6 months as part of the protocol assessment in the
NOR-DMARD project.15 The results from these questionnaires
were not accessible to the assessors during the ICF interviews.
Measures at these two time points included pain, fatigue and
patient global assessment of disease activity (all 0–100 mm
visual analogue scales), Modified Health Assessment
Questionnaire (MHAQ)16 and the Short-Form 36 (SF-36) health
survey.17 Physical and mental component summary scores (PCS
and MCS, respectively) were aggregated from the SF-36.18 The
utility measure (SF-6D) was derived from the responses to the
SF-36 questionnaire based on an algorithm developed by
Brazier.19
A health transition item was used as external indicator of
improvement with the question: ‘‘Has your overall health
improved since the start of the study?’’ with response options
‘‘yes/no’’.
Disease activity
A total of 28 swollen and tender joint counts were performed
and the 28-joint Disease Activity Score (DAS28) was calculated
from joint counts, patient global assessment and erythrocyte
sedimentation rate.20 Achievement of European league Against
Rheumatism (EULAR) moderate response21 was assessed after 6
months.
Data analysis and statistics
Descriptive statistics and distribution with frequencies and
proportions were used to describe ICF categories, demographics
and clinical characteristics. For categorical variables we used
counts with percentages, continuous data are presented as
means with standard deviations (SD). A paired Student t test
was applied to examine improvement of continuous health
status or disease activity measures.
We examined internal and external responsiveness.22 To
examine internal responsiveness of the individual ICF categories
we calculated the percentage of patients improving in function-
ing by one or two response levels, remaining unchanged or
worsening by one or two response levels. We defined a clinically
relevant change in an individual ICF category when after
6 months DMARD treatment the response level was scored at
least one level better or worse.
We also summed up in each patient the number of all
qualifier changes in the 96 categories of the ICF Core Set for RA
(number of qualifiers with improvement minus number of
qualifiers with worsening) and in each functioning component.
Changes in ICF components, patient-reported outcomes and
disease activity among patients with and without improvement
in health were calculated as a measure for effect size as
standardised response means (change over 6 months/SD of the
change). We applied Cohen standards for effect sizes23 as: small
effect 0.2, medium effect 0.5 and large effect 0.8, and presented
them together with p values from the unpaired Student t test as
recommended.24
For examination of external responsiveness of the ICF during
DMARD treatment we also compared changes in ICF compo-
nents and overall in the ICF Core Set for RA with 6-month
changes in health status instruments (MHAQ, SF-36), SF-6D
and disease activity (DAS28), using Spearman rho correlation
coefficients. The use of a transition item for improvement
facilitates interpretation of the discriminative ability.25
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A correlation coefficient below 0.40 was considered to
indicate a low correlation and a value of 0.40 to 0.59 a moderate
correlation.
The level of significance was set to p,0.05. All statistical
analyses were performed using SPSS V. 14.0 statistical software
(SPSS Inc, Chicago, IL, USA). The regional ethics committee
approved the study.
RESULTS
Demographic data and clinical characteristics of the participants
are shown in table 1 for completers (n = 46) and non-completers
(n = 15). Reasons for non-completion were declination or
practical difficulty to meet for a new scheduled ICF interview
(n = 12) in addition to the clinical routine follow-up visit and
lack of clinical data when the specific DMARD regime was
terminated (n = 3) before 6 months follow-up.
The health transition item indicated that the majority of the
patients considered their health improved (27 of 46, 59%) after
6 months with DMARD treatment.
For all individual ICF categories with baseline values for
impairment and 6-month changes in the different components
Body Functions, Body Structures and Activities and
Participation, and Environmental Factors, see Supplementary
material. The two most responsive individual categories in this
study were s73011 ‘‘Wrist joint’’ and e115 ‘‘Products and
technology for personal use in daily living’’ where 58% of
patients had improved and 43% had obtained more support,
respectively, over 6 months (Supplementary material). Of 46
patients, no problems in any of the component categories at
baseline were present for 0 patients for Body Functions, for 1
patient for Body Structures, for 1 patient for Activities and
Participation and for 5 patients for Environmental Factors.
Table 2 displays the mean number with range for impair-
ments present for patients at baseline and follow-up and
presents mean frequency of patients improving, staying
unchanged and worsening in the different ICF components
and overall for all 96 categories in the ICF Core Set for RA. In
all, 20% of patients had improvement with at least one response
level averaged through all ICF categories, 71% experienced no
change and 9% worsening. Findings for change in ICF categories
were consistent through the four components of functioning.
Mean changes and effect sizes for ICF components of
functioning and for measures for patient-reported outcomes
and disease activity and utility are presented in table 3 for all
patients, and for patients with and without overall improve-
ment over 6 months. During the 6-month treatment period
disease activity (DAS28) improved within the patient group
with mean (SD) 0.58 (0.77) (p,0.001, paired t test). Physical
function improved within the whole patient group by mean
0.16 (0.46) (p = 0.01) for MHAQ and mean 3.5 (8.7) (p = 0.02)
for SF-36 PCS, whereas mental function (SF-36 MCS) improved
by mean 4.2 (11.0) (p = 0.02) and SF-36 derived utility by 0.07
(0.12) (p = 0.001) (table 3).
The mean sum of qualifier changes in the ICF Core Set in RA
was numerically, but not statistically significantly, higher in
improved versus non-improved patients without improved
health (13.9 vs 7.0, p = 0.08) (table 3). Similar patterns were
observed in the different domains of functioning, but were
statistically significant only for the component Body Functions
(table 3). Effect sizes were moderate for three ICF components,
were small for one component and were higher for patients
with improvement than for non-improved patients. Effect sizes
for changes in the ICF Core Set in RA (0.83) and for disease
activity (0.75) were moderate to high and were comparable
(table 3).
Correlation coefficients between changes in ICF categories
and changes in patient-reported health status, utility and
disease activity are displayed in table 4. Patients were also
examined separately dependent on whether they considered
their health status improved or not according to the transition
question. We found only low correlation between changes in
ICF components and patient-reported outcomes, utility and
disease activity with statistical significance for the association
between disease activity and ICF components, however with
the exception of Environmental Factors (table 4).
DISCUSSION
This study is the first to examine how ICF categories change
during treatment of RA. Over 6 months treatment with
DMARD on average 20% of patients had improvement by one
or two qualifiers through all 96 categories contained in the ICF
Core Set for RA. The majority of patients remained unchanged
however and a worsening of functioning was present overall in
9% of patients. Interestingly, the specified problems with
functioning changed consistently through all components
Body Functions and Structures, Activities and Participation,
and Environmental Factors.
Our examination of external responsiveness comparing the
ICF to established health status instruments showed very low
correlation coefficients and no consistent and convincing
results. Mainly moderate effect sizes were observed during
DMARD treatment in the different ICF components, but were
comparable with patient-reported outcomes and disease activ-
ity. Between improved and non-improved patients statistically
significant changes were only observed for Body Functions,
which was expected as physiological functions rather than
Table 1 Demographic characteristics and baseline scores for health
status measures and disease activity in completers and non-completers
(means (SD) for continuous variables, % for counts)
Completers
(n = 46)
Non-completers
(n = 15)
Age (years) 53.6 (12.6) 53.3 (10.7)
Female 72% 53%
Disease duration (years) 6.3 (8.0) 6.1 (8.9)
Rheumatoid factor positive 80% 87%
Erosive disease (present) 50% 47%
Education level high (.12 years) 43% 40%
Pain (100 mm VAS) 47 (23) 40 (23)
Fatigue (0–100 mm VAS) 52 (29) 37 (27)
Patient global (0–100 mm VAS) 52 (25) 39 (22)
MHAQ (1–4) 1.7 (0.5) 1.6 (0.5)
SF-36 PCS (0–100) 30 (9.9) 35 (6.6)
SF-36 MCS (0–100) 45 (11.0) 49 (8.5)
DAS28 5.1 (1.3) 4.2 (1.3)
Glucocorticoids (current use) 57% 73%
NSAID (current use) 29% 27%
Cyclo-oxygenase 2 inhibitors (current
use)
5% 7%
DMARD initiated at baseline:
Monotherapy 65% 67%
Combination 11% 20%
Biological agent 24% 13%
DAS28, 28-joint Disease Activity Score; MCS, mental component summary; MHAQ,
Modified Health Assessment Questionnaire; NSAID, non-steroidal antirheumatic drug;
PCS, physical component summary; SF-36, Short Form 36; VAS, visual analogue
scale.
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anatomical structures are the target for interventions with
DMARDs. The association of changes in ICF categories with
measures of patient-reported outcomes, utility and disease
activity was low and independent of whether patients
improved. Changes in Environmental Factors were small, also
leading to absence of significant correlation with changes in
MHAQ and SF-36.
In real-life settings such as ours, health improvements may
appear on a smaller scale than in randomised controlled trials. In
our 6-month study improvements on a group level were small
for health status (0.16 for MHAQ, 3.5 and 4.2 units for SF-36
PCS and MCS, respectively) and 0.58 for DAS28. These mean
changes are below or around the limits for minimal clinically
important changes as defined by the patient,26 for physical
function,27 the SF-36 instrument,28 and correspond to a
moderate response in disease activity.21 Against this background
of limited improvements among patient-reported outcomes it is
noteworthy that the ICF still captures small changes as
observed in a real-life setting with DMARD treatment as a
case in point. The intervention in our study could as such serve
only as a model for minor effects, typically found in real-life
practice, especially when one does not measure the exact targets
of the interventions. As a consequence, every statistical exercise
is blurred by the very limited true effects, and in more diseased
populations of patients with RA a higher responsiveness of the
ICF might be seen.
Our findings are novel results in a new field. Given the
adoption of the ICF by the WHO as a classification tool for
global application, extensive testing of the ICF is required. In
osteoarthritis the ICF Core Set for osteoarthritis has recently
been validated,29 however to date there are no published results
on responsiveness of any ICF Core Sets. Recently the reliability
of the ICF Core Set for RA was found to be low and at best
moderate.13 As a consequence of low reliability also responsive-
ness will be compromised. While reliability could be improved
by reducing the numbers of qualifiers from five to three, it is not
clear how a higher number of qualifiers would have impacted
responsiveness in this study. So far there are no other studies on
responsiveness of ICF Core Sets in RA or other diseases.
The ICF was not designed as a measure of health status and
we in this study do not suggest calculating ICF scores; the main
objective of the ICF is to describe important aspects of health
and not to measure them. Our definition of responsiveness as a
change of one or more qualifiers in one respective ICF category
(for example from severe to moderate impairment) has high face
validity and relates to an immediate context. It has been
highlighted that responsiveness should be contextualised rather
than being considered a static attribute.30
A limitation of this study is that it was conducted at a single
centre and our findings may not be extrapolated to other
environments of patients and health professionals. Further, the
reduction of the number of response levels has increased
feasibility and the robustness of findings at the cost of
increasing the threshold for demonstrating responsiveness.
With a higher number of response levels as in the original ICF
qualifier scale, higher responsiveness would most likely have
Table 2 Mean number (range) of categories with impairments at baseline and follow-up by International Classification of Functioning, Disability and
Health (ICF) Core Set for rheumatoid arthritis (RA) component and proportions of patients (%) with impairment changes over 6 months in components
Impairments at
baseline (n)
Impairments at
follow-up (n)
Improvement Unchanged Worsening
2 Qualifiers 1 Qualifier 0 Qualifiers 1 Qualifier 2 Qualifiers
Body functions
(n = 25)
13.8 (3 to 20) 11.0 (0 to 22) 1% 20% 71% 8% 0%
Body structures
(n = 18)
8.0 (0 to 16) 6.5 (0 to 13) 1% 18% 73% 8% 0%
Activities and
participation (n = 32)
13.1 (0 to 27) 9.2 (1 to 25) 1% 20% 70% 8% 0%
Environmental factors
(n = 21)
3.3 (0 to 11) 1.9 (0 to 7) 3% 16% 68% 12% 0%
All categories
(n = 96)
38.1 (7 to 70) 28.6 (1 to 62) 1% 19% 71% 9% 0%
Table 3 Mean change and effect size (standardised response mean) in the International Classification of Functioning, Disability and Health (ICF) Core
Set for rheumatoid arthritis (RA) components and health status, utility (Short-Form 6D (SF-6D)) and disease activity (28-joint Disease Activity Score
(DAS28)) over 6 months with disease-modifying antirheumatic drug (DMARD) treatment presented for patients with and without improvement in health
All patients (n = 46)
Patients with improved health
(n = 27)
Patients without improved health
(n = 19)
p Value*Change Effect size Change Effect size Change Effect size
ICF: Body Functions 23.1 (5.3) 0.59 24.5 (5.0) 0.85 21.2 (5.2) 0.22 0.03
ICF: Body Structures 21.8 (4.5) 0.41 22.3 (4.1) 0.50 21.3 (5.1) 0.27 0.47
ICF: Activities and Participation 24.3 (6.0) 0.71 25.1 (6.7) 0.85 23.1 (4.8) 0.51 0.27
ICF: Environmental Factors 21.8 (3.3) 0.53 22.0 (3.6) 0.59 21.5 (3.0) 0.44 0.63
All ICF categories 211.0 (13.2) 0.83 213.9 (13.5) 1.05 27.0 (11.9) 0.53 0.08
MHAQ 20.16 (0.46) 0.35 20.28 (0.43) 0.60 0.01 (0.45) 0.01 0.04
SF-36 PCS 3.5 (8.7) 0.41 6.4 (7.9) 0.74 0.3 (8.6) 0.03 0.01
SF-36 MCS 4.2 (11.0) 0.38 5.1 (10.0) 0.46 3.0 (12.2) 0.28 0.55
SF-6D 0.07 (0.12) 0.56 0.09 (0.12) 0.75 0.04 (0.12) 0.32 0.17
DAS28 20.58 (0.77) 0.75 20.80 (0.85) 1.04 20.27 (0.53) 0.34 0.01
*t Test comparing patients with improved versus patients without improved health.
MCS, mental component summary; MHAQ, Modified Health Assessment Questionnaire; PCS, physical component summary; SF-36, Short Form 36.
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been demonstrated. A transition item may be more useful for
validation and exploring interpretability of an instrument than
for definition of responsiveness.31
A strength of this study is examination of patients with RA in
need of medical treatment in a longitudinal setting from clinical
practice. This adds external validity to our findings. Patients in
our sample represent the typical average age group of patients
with RA in our outpatient clinic,32 which provides rheumatol-
ogy services to the population of Oslo, Norway. Both assessors
in this study were experienced clinicians with extensive
experience with the ICF concept.
In conclusion, this study demonstrates moderate responsive-
ness of the ICF RA Core Set in patients with RA who were
treated in a real-life setting where smaller changes in patient-
reported outcomes are observed than in recent randomised
controlled trial with biological drugs.33 The importance of
further testing of the ICF Core Set for RA is apparent as the ICF
has been adopted by the WHO, and in particular before
applicability of the ICF in clinical rheumatology is considered.
The ICF is an ongoing process, where testing from clinical
settings such as ours and suggestions for further improve-
ment—including testing of self-report questionnaires—continu-
ously needs to be addressed.
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